Keryx Biopharmaceuticals Inc. (KERX): Health Care's Highlighted Dud Of The Day

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Keryx Biopharmaceuticals ( KERX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.1%. By the end of trading, Keryx Biopharmaceuticals fell 7 cents (-1%) to $6.90 on light volume. Throughout the day, 1.3 million shares of Keryx Biopharmaceuticals exchanged hands as compared to its average daily volume of 7.9 million shares. The stock ranged in price between $6.85-$7 after having opened the day at $7 as compared to the previous trading day's close of $6.97. Other companies within the Health Care sector that declined today were: ZIOPHARM Oncology ( ZIOP), down 64.5%, Stereotaxis ( STXS), down 17.6%, CEL-SCI Corporation ( CVM), down 12.6%, and Strategic Diagnostics ( SDIX), down 10.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. Keryx Biopharmaceuticals has a market cap of $577.5 million and is part of the drugs industry. Shares are up 166% year to date as of the close of trading on Monday. Currently there are six analysts that rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins.

On the positive front, Bovie Medical Corporation ( BVX), up 28.7%, Opexa Therapeutics ( OPXA), up 23.7%, USMD Holdings ( USMD), up 12.3%, and Accelerate Diagnostics ( AXDX), up 10.9%, were all gainers within the health care sector with Johnson & Johnson ( JNJ) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

5 Breakout Stocks Under $10 Set to Soar

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)